Aptamer-based therapeutics and their potential in radiopharmaceutical design
Aptamer-based therapeutics and their potential in radiopharmaceutical design
复制标题
DOI：
10.1590/s1516-89132007000600008
复制
发表时间：
2007-09-01
影响因子：
1
通讯作者：
Missailidis, Sotiris
中科院分区：
文献类型：
--
作者：
Ferreira, Catia S. M.;Missailidis, Sotiris
在过去的15年中，针对过多的靶标和用于各种应用，已经开发了短的单链寡核苷酸实体适体。这些范围从受体和酶的抑制到传感器应用中小分子的识别，以及从靶向治疗剂的开发到新型诊断和成像剂的设计。此外，适体已被设计用于涵盖从艾滋病毒到热带疾病、癌症和炎症等广泛疾病的靶标。它们易于开发，使用和操作灵活，提供了进一步的潜力。在本文中，我们回顾了它们的选择，并考虑了一些最近的应用适体在设计的放射性药物的靶向放射治疗和疾病的医学成像。
Aptamers, short, single stranded oligonucleotide entities, have been developed in the past 15 years against a plethora of targets and for a variety of applications. These range from inhibition of receptors and enzymes to the identification of small molecules in sensor applications, and from the development of targeted therapeutic to the design of novel diagnostic and imaging agents. Furthermore, aptamers have been designed for targets that cover a wide range of diseases, from HIV to tropical diseases, cancer and inflammation. Their easy development and flexibility of use and manipulation, offers further potential. In this paper we review their selection and consider some of the recent applications of aptamers in the design of radiopharmaceuticals for the targeted radiotherapy and medical imaging of disease.